In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy.

Intracranial studies to analyze the degradation kinetics of the bioerodible polymer poly[bis(p-carboxyphenoxy)propane-sebacic acid] [p(CPP-SA) 20:80] copolymer wafers were conducted in a rat model. Rats were separated into four groups: those receiving 1) polymer, 2) polymer loaded with the chemotherapeutic agent BCNU, 3) drug-loaded polymer with previous tumor implantation, and 4) polymer and an absorbable hemostatic material. A polymer wafer was surgically implanted into the brain of each animal. Residual polymer was harvested at varying times for chromatographic analysis. In vitro effects of pH, mixing, and water availability on degradation were also studied. The results of in vitro and in vivo studies were compared to understand the behavior of polymers in a clinical setting. We found that degradation of p(CPP-SA) initially occurred more slowly in vivo than in vitro. The presence of BCNU, tumor, and absorbable hemostatic material did not affect the ultimate time of polymer degradation in vivo, and the intrinsic polymer degradation time of 1 mm thick p(CPP-SA) 20:80 disks in vivo was 6-8 weeks.

[1]  T J Ebner,et al.  Sustained release of nerve growth factor from biodegradable polymer microspheres. , 1992, Neurosurgery.

[2]  D. Rottenberg,et al.  In vivo measurement of brain tumor pH using [11C]DMO and positron emission tomography , 1985, Annals of neurology.

[3]  H. Winn,et al.  Intracerebral drug delivery in rats with lesion-induced memory deficits. , 1989, Journal of neurosurgery.

[4]  P. Aebischer,et al.  NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion , 1990, Experimental Neurology.

[5]  B. Glasgow,et al.  Use of bioerodible polymers impregnated with mitomycin in glaucoma filtration surgery in rabbits. , 1991, Ophthalmology.

[6]  A. Friedman,et al.  Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. , 1991, Journal of neurosurgery.

[7]  Robert Langer,et al.  Polyanhydrides. I: Preparation of high molecular weight polyanhydrides , 1987 .

[8]  R Langer,et al.  Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. , 1985, Journal of Biomedical Materials Research.

[9]  R. Tamargo,et al.  Angiogenesis inhibition by minocycline. , 1991, Cancer research.

[10]  R. Tamargo,et al.  Brain biocompatibility of a biodegradable, controlled-release polymer in rats. , 1989, Journal of biomedical materials research.

[11]  B. Khoobehi,et al.  Clearance of sodium fluorescein incorporated into microspheres from the vitreous after intravitreal injection. , 1991, Ophthalmic surgery.

[12]  C. Fournier,et al.  Experimental studies and preliminary clinical trial of vinorelbine-loaded polymeric bioresorbable implants for the local treatment of solid tumors. , 1991, Cancer research.

[13]  D. Long,et al.  Interstitial delivery of dexamethasone in the brain for the reduction of peritumoral edema. , 1991, Journal of neurosurgery.

[14]  R. Langer,et al.  Interstitial Drug Therapy for Brain Tumors: A Case Study , 1990 .

[15]  A Deutch,et al.  Controlled release of dopamine from a polymeric brain implant: In vivo characterization , 1989, Annals of neurology.

[16]  H. Yamanaka,et al.  In vivo characteristics of low molecular weight copoly (D,L-lactic acid) formulations with controlled release of LH-RH agonist. , 1989, Biomaterials.

[17]  D. Lenartz,et al.  Interstitial Chemotherapy with Drug Impregnated Polymer Implants to Treat Brain Tumors: Pre-Clinical and Clinical Studies , 1991 .

[18]  B. Sabel,et al.  Extended levodopa release from a subcutaneously implanted polymer matrix in rats , 1990, Annals of neurology.

[19]  S. Hjorth,et al.  Microencapsulated Dopamine (DA)-Induced Restitution of Function in 6-OHDA-Denervated Rat Striatum in vivo: Comparison Between Two Microsphere Excipients , 1991, Journal of neural transplantation & plasticity.

[20]  H. Brem,et al.  Polymers to treat brain tumours. , 1990, Biomaterials.

[21]  R. Langer,et al.  Polyanhydrides as drug delivery systems , 1990 .

[22]  J. Hilton,et al.  Polymeric controlled release of dexamethasone in normal rat brain , 1991 .

[23]  R. Tamargo,et al.  The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. , 1992, Journal of neurosurgery.

[24]  K. Judy,et al.  Controlled release of 4-hydroperoxycyclophosphamide from the fatty acid dimer-sebacic acid copolymer , 1992 .

[25]  Fred H. Hochberg,et al.  Assumptions in the radiotherapy of glioblastoma , 1980, Neurology.

[26]  R. Tamargo,et al.  Biocompatibility of a biodegradable, controlled-release polymer in the rabbit brain. , 1989, Selective cancer therapeutics.

[27]  R. Tamargo,et al.  Controlled delivery of 1,3-bis(2-chloroethyl)-1-nitrosourea from ethylene-vinyl acetate copolymer. , 1989, Cancer research.

[28]  S. Jain,et al.  Polymeric pseudolatices bearing pilocarpine for controlled ocular delivery. , 1992, Journal of microencapsulation.

[29]  Shelley R. Winn,et al.  Behavioral recovery following intrastriatal implantation of microencapsulated PC12 cells , 1991, Experimental Neurology.

[30]  Y. Ikada,et al.  Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. , 1991, Investigative ophthalmology & visual science.

[31]  W. Hayes,et al.  Bioerodible polyanhydrides for antibiotic drug delivery: In vivo osteomyelitis treatment in a rat model system , 1993, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[32]  M. Mayberg,et al.  Localized release of perivascular heparin inhibits intimal proliferation after endothelial injury without systemic anticoagulation. , 1989, Neurosurgery.